Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Is CVS Group plc Falling -4.92% Today? Key Reasons Investors Are Watching CVS Group plc — LSE:CVSG

CVS Group plc — LSE:CVSG is in focus after a 4.92% decline on 1 October 2026 despite recently reporting a solid full-year performance. CVS reported FY2026Revenueof £712.8m, up 5.9%, with like-for-like sales growth of 2.1%. Australian revenue rose to £79.1m and represented about 11% …

Ankur Sharma | 01 October 2026

Why Is Arecor Therapeutics PLC (LSE:AREC) in Focus After a 3.45% Rise on 1 October 2026?

• Arecor Therapeutics is in focus after a busy late-September period that included interim results and a proposed fundraising of up to £5.13 million. The company develops improved formulations of medicines using its Arestat technology platform, with a particular focus on diabetes and cardiometabolic …

Ankur Sharma | 01 October 2026

Why Is EKF Diagnostics Holdings plc (LSE:EKF) in Focus After a 3.25% Rise on 1 October 2026?

• EKF Diagnostics is in focus as the diagnostics specialist showcases its point-of-care and laboratory technologies at EAHS Africa in Nairobi on 1–2 October 2026. The company is presenting products including the DiaSpect Tm and Hemo Control haemoglobin systems and Quo-Lab and Quo-Test HbA1c …

Ankur Sharma | 01 October 2026

Why Is Fusion Antibodies Plc (LSE:FAB) in Focus After a 3.65% Rise on 1 October 2026?

• Fusion Antibodies is in focus as the biotechnology services company continues to develop its pre-clinical antibody discovery, engineering andSupplyactivities. A notable recent development was the grant of a CanadianPatentfor its OptiMAL technology in September 2026. The patent covers antibody-library technology and supports the …

Ankur Sharma | 01 October 2026

Why Is Renalytix PLC (LSE:RENX) in Focus After a 3.28% Rise on 1 October 2026?

• Renalytix is in focus as the precision-medicine diagnostics company advances commercialisation of KidneyIntelX.dkd, its kidney-disease risk assessment technology. A major recent development was a multi-year agreement with Quest Diagnostics to expand availability of KidneyIntelX.dkd in the United States. The company also completed a …

Ankur Sharma | 01 October 2026

SkinBioTherapeutics Shares Rise 8% as New Leadership Settles In and Early FY27 Trading Beats Expectations (LSE:SBTX)

SkinBioTherapeutics is a Newcastle-based life science company focused on skin health. Its proprietary SkinBiotix platform originates from research at the University of Manchester. The company sells AxisBiotix food supplements targeting the gut-skin axis, aimed at conditions such as psoriasis, acne and eczema. These products …

Ankur Sharma | 01 October 2026

AOTI, Inc. (LSE:AOTI) Jumps 3.85%: Why the Stock Is in Focus on 1 October 2026

The 3.85% gain indicates a clear improvement in near-term trading sentiment. In smaller and mid-cap shares, a positive session can be amplified by limited liquidity, fresh corporate information, sector rotation or investors repositioning ahead of expected milestones. For AOTI, Inc. (LSE:AOTI), the latest company …

Ankur Sharma | 01 October 2026

Eden Research plc (LSE:EDEN) Jumps 4.35%: Why the Stock Is in Focus on 1 October 2026

The 4.35% gain indicates a clear improvement in near-term trading sentiment. In smaller and mid-cap shares, a positive session can be amplified by limited liquidity, fresh corporate information, sector rotation or investors repositioning ahead of expected milestones. For Eden Research plc (LSE:EDEN), the latest …

Ankur Sharma | 01 October 2026

HemoGenyx Pharmaceuticals Plc (LSE:HEMO) Jumps 3.77%: Why the Stock Is in Focus on 1 October 2026

The 3.77% gain indicates a clear improvement in near-term trading sentiment. In smaller and mid-cap shares, a positive session can be amplified by limited liquidity, fresh corporate information, sector rotation or investors repositioning ahead of expected milestones. For HemoGenyx Pharmaceuticals Plc (LSE:HEMO), the latest …

Ankur Sharma | 01 October 2026

CRISM Therapeutics Corporation (LSE:CRTX) Jumps 5.26%: Why the Stock Is in Focus on 1 October 2026

CRISM Therapeutics Corporation (LSE:CRTX) advanced 5.26% on 1 October 2026, placing the stock among the stronger movers in its part of the UK market. The gain has increased investor attention at a time when small- and mid-cap shares are reacting sharply to fresh corporate …

Ankur Sharma | 01 October 2026
Support

Hi! How can we help you today?

Loading…